Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Nat Genet. 2020 Feb;52(2):208-218. doi: 10.1038/s41588-019-0572-y. Epub 2020 Feb 3.
Cancer genomes contain large numbers of somatic mutations but few of these mutations drive tumor development. Current approaches either identify driver genes on the basis of mutational recurrence or approximate the functional consequences of nonsynonymous mutations by using bioinformatic scores. Passenger mutations are enriched in characteristic nucleotide contexts, whereas driver mutations occur in functional positions, which are not necessarily surrounded by a particular nucleotide context. We observed that mutations in contexts that deviate from the characteristic contexts around passenger mutations provide a signal in favor of driver genes. We therefore developed a method that combines this feature with the signals traditionally used for driver-gene identification. We applied our method to whole-exome sequencing data from 11,873 tumor-normal pairs and identified 460 driver genes that clustered into 21 cancer-related pathways. Our study provides a resource of driver genes across 28 tumor types with additional driver genes identified according to mutations in unusual nucleotide contexts.
癌症基因组包含大量体细胞突变,但其中只有少数突变会驱动肿瘤的发展。目前的方法要么根据突变的重现率来识别驱动基因,要么通过生物信息学评分来近似非同义突变的功能后果。过客突变富集在特征核苷酸背景中,而驱动突变发生在功能位置,这些位置不一定被特定的核苷酸背景所包围。我们观察到,偏离过客突变周围特征背景的突变提供了支持驱动基因的信号。因此,我们开发了一种方法,将这一特征与传统用于鉴定驱动基因的信号相结合。我们将该方法应用于 11873 对肿瘤-正常样本的全外显子测序数据中,鉴定出 460 个驱动基因,这些基因聚类为 21 个与癌症相关的通路。我们的研究提供了 28 种肿瘤类型的驱动基因资源,并根据异常核苷酸背景中的突变进一步确定了额外的驱动基因。